Please add info@sitcancer.org to your safe senders list.
Tuesday, May 31, 2016
Message from the President
Dear Colleagues,
For over 30 years, the Society for Immunotherapy of Cancer (SITC) has been the leader in promoting tumor immunology and bringing cancer immunotherapy education, information and research to the field. This effort was made possible by our diverse and committed membership and through key strategic partnerships. Toward this end, I am pleased to announce a new SITC collaborative relationship with the American Society of Clinical Oncology (ASCO) and the National Coalition for Cancer Research.
Our relationship with ASCO comes at a historic time when immunotherapy is becoming established as a standard approach to the treatment of cancer. SITC is pleased to collaborate with ASCO to bring the latest knowledge and advances in patient management to physicians and other health care providers through various targeted educational programs and events.
The National Coalition for Cancer Research is based on the belief that research cures cancer and are dedicated to the eradication of cancer through a vigorous public and privately-supported research effort. We believe that this mission strongly aligns with our society mission. To that end, we are happy to become the first cancer immunotherapy-focused organization to be part of the coalition. SITC has been warmly welcomed into the organization with unanimous coalition board approval. This relationship enables SITC members to be at the front lines on policy and legislative matters regarding cancer immunotherapy and patient care.
Through these relationships, SITC will be able to further reach stakeholders at all levels to disseminate tumor immunology and cancer immunotherapy information in order to improve cancer patient outcomes.
I would like to thank each one of you for your continued dedication and work to the field of cancer immunotherapy. It is because of you that cancer immunotherapy is making “cure” a reality for patients everywhere.
Best regards,
Howard L. Kaufman, MD, FACS
ASCO and SITC Collaboration
“Immunotherapy is rapidly transforming the treatment of patients with cancer,” said ASCO President Julie M. Vose, MD, MBA, FASCO. “Together, ASCO and SITC can help equip the oncology community with the necessary knowledge and resources to effectively integrate immunotherapy into their patient care.”
Currently, ASCO and SITC have three upcoming educational programs for oncology professionals:
- How to Integrate Tumor Immunotherapy Into Your Clinical Practice
June 2 – 3, 2016 • Chicago, Illinois
Held leading into the 2016 ASCO Annual Meeting, this Pre-Annual Meeting Seminar will target the needs of clinical oncologists and the entire medical team involved in treating cancer patients. This program will provide an understanding of basic immunology principles, the clinical application of modern cancer immunotherapy, management of patients receiving immunotherapy, and emerging drugs and concepts in the field, including a focus on the value proposition of immunotherapy agents for patients and clinical practices.
- Value of Cancer Immunotherapy Summit
November 13, 2016 • National Harbor, Maryland
This summit will discuss the issues of value with respect to tumor immunology and cancer immunotherapy, bringing a variety of different perspectives to the table, including academic physicians, patient advocates, regulatory agencies and third party payers. In addition to articulating the unique features of cancer immunotherapy, the summit is expected to result in a referendum on future directions and priorities for better defining the full value of this form of treatment for patients with cancer.
- Inaugural ASCO-SITC Clinical Immuno-Oncology Symposium
February 23-25, 2017 • Orlando, Florida
This three-day meeting will focus on clinical and translational research in immuno-oncology and the implications for clinical care. The symposium will address the high level of need for up-to-date information in a rapidly changing field as well as clinical education in an area in which all aspects of care are fundamentally different from traditional therapies. Expert faculty will contextualize the latest science for clinical application, with formal opportunities for networking, discussion and interaction.
These educational opportunities come at a time in which it is crucial for clinical oncologists to learn about the expanding options for cancer care. The collaborative programs that ASCO and SITC have developed aim to educate those who are face-to-face with patients every day.
National Coalition for Cancer Research and SITC Collaboration
“Given the extraordinary impact immunotherapy is having, and will continue to have, on cancer research, this is an important addition to our membership.” National Coalition for Cancer Research President Wendy K. D. Selig, MS
SITC is one of the oldest and most credible professional organizations dedicated to improving cancer patient outcomes by the implementation of cancer immunotherapy. SITC’s acceptance into the coalition is a promising next step in promoting cancer immunotherapy research and policies as it becomes a standard of care and puts SITC members at the forefront of legislative and policy initiatives.
Society for Immunotherapy of Cancer (SITC)
555 East Wells Street, Suite 1100 | Milwaukee, Wisconsin 53202-3823 USA
Phone: +1 414 271 2456 | Email: info@sitcancer.org
© 2016 Society for Immunotherapy of Cancer
Join us on:
If you do not wish to be included in our mailing list, please forward this message to info@sitcancer.org with the word "Remove" in the subject line.
Please add info@sitcancer.org to your safe senders list.